CN108195962A - 一种特非那定有关物质的检验分离方法 - Google Patents

一种特非那定有关物质的检验分离方法 Download PDF

Info

Publication number
CN108195962A
CN108195962A CN201711450984.3A CN201711450984A CN108195962A CN 108195962 A CN108195962 A CN 108195962A CN 201711450984 A CN201711450984 A CN 201711450984A CN 108195962 A CN108195962 A CN 108195962A
Authority
CN
China
Prior art keywords
impurity
rmi
substance
relation
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201711450984.3A
Other languages
English (en)
Other versions
CN108195962B (zh
Inventor
田娟
曹元敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JIANGSU LIANHUAN PHARMACEUTICAL CO Ltd
Original Assignee
JIANGSU LIANHUAN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGSU LIANHUAN PHARMACEUTICAL CO Ltd filed Critical JIANGSU LIANHUAN PHARMACEUTICAL CO Ltd
Priority to CN201711450984.3A priority Critical patent/CN108195962B/zh
Publication of CN108195962A publication Critical patent/CN108195962A/zh
Application granted granted Critical
Publication of CN108195962B publication Critical patent/CN108195962B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

本发明公开了一种特非那定有关物质的检验分离方法,包括以下步骤:1)分别取各杂质及TFND适量,加70%乙腈制成10µg/mL的单一溶液,在190nm~400nm波长进行全波长扫描,获得各物质的扫描波长,确定紫外扫描检测波长;2)配制用于检测的混合溶液;3)色谱条件:色谱柱:MZ‑ANALYTICAL Column 250*4.6mm 100ODS‑3 5μm;流动相A:乙腈‑磷酸盐=20︰80;流动相B:乙腈;梯度洗脱:0min,60%A,40%B;3min,55%A,45%B;20min,20%A,80%B;溶剂:乙腈‑磷酸盐=45:55;波长:217nm;流速:1.0mL/min;柱温:30‑35℃;进样量:20μL;4)取混合溶液进样,记录色谱图,特非那定与各杂质均获得分离。本发明的特非那定与杂质分离度大于5.0,各杂质间、其它已知杂质与特非那定间的分离度均大于1.5,且主峰和未知杂质分离度可达3.5,符合要求。

Description

一种特非那定有关物质的检验分离方法
技术领域
本发明属于药物杂质检验技术领域,具体涉及一种特非那定(Terfenadine) 有关物质的检验方法。
背景技术
特非那定是特非那定颗粒(商品名:敏迪)的主要成分,用于季节性和非季节性过敏性鼻炎、荨麻疹及枯草热的治疗。特非那定是特异H1受体阻断剂,在抗组胺有效剂量下,特非那定是及其代谢产物均不易透过血脑屏障,故极少有中枢抑制作用。
特非那定(Terfenadine)是Carr等于1973年创制、美国Merrell制药公司于 1981年首先上市,目前已在欧美各国广泛使用。中国药典2010版二部检测项下并没有对该片剂有关物质的检测进行规定,而在世界上的其他国家,相关规定也并不明确,因此为进一步有效控制药品质量、完善质量标准,需对特非那定有关物质的检验。
陈柳生等在“特非那定片有关物质的检测方法研究”一文中公开了建立特非那定片的有关物质高效液相色谱检查法(HPLC)。方法采用HPLC法,使用 HypersilPhenyl2(250×4.6mm,5μm)色谱柱,流动相为缓冲液-乙腈-三乙胺(650∶ 350∶3;检测波长为220nm;流速为1.5mL·min-1;柱温为室温。结果该色谱条件下,杂质与主成分能完全分离,重复性试验RSD为0.27%(n=6),最低检测量为0.005μg,有关物质含量均为0.3%。结论该方法简便、准确、灵敏度高,可用于特非那定片中杂质含量的测定。该方法在一定程度上实现杂质与主成分能完全分离,但当杂质含量较多的时候,并不能完全有效实现分离,还不能完全满足使用需求。
发明内容
发明目的:针对现有技术中存在的不足,本发明的目的是提供一种特非那定有关物质的检验分离方法,实现特非那定有关物质的快速全部分离。
技术方案:为了实现上述发明目的,本发明采用的技术方案为:
一种特非那定有关物质的检验分离方法,包括以下步骤:
1)分别取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND适量,加70%乙腈制成10μg/mL的单一溶液,在 190nm~400nm波长进行全波长扫描,获得各物质的扫描波长,确定紫外扫描检测波长;
2)配制混合溶液:取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND各适量,加溶剂配制成每1mL含杂质 A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质 J各1.0μg、TFND 1.0mg的混合溶液;
3)色谱条件:色谱柱:MZ-ANALYTICAL Column 250*4.6mm 100ODS-3 5μm;流动相A:乙腈-磷酸盐=20︰80;流动相B:乙腈;梯度洗脱:0min,60%A, 40%B;3min,55%A,45%B;20min,20%A,80%B;溶剂:乙腈-磷酸盐=45: 55;波长:217nm;流速:1.0mL/min;柱温:30-35℃;进样量:20μL;
4)取混合溶液进样,记录色谱图,特非那定与各杂质均获得分离。
步骤1)中,检测波长为217nm。
步骤3)中,磷酸盐溶液配制方法为:3.58g十二水合磷酸氢二钠溶于1000mL 水中,磷酸调pH至6.0-6.3,再加入1.92g SDS溶解过滤。
步骤3)中,磷酸盐溶液的pH为6.0。
步骤3)中,流动相B:乙腈-甲醇=95︰5。
步骤3)中,梯度洗脱:0min,40%A,60%B;10min,40%A,60%B;20min, 20%A,80%B。
步骤3)中,柱温:30℃。
步骤3)中,梯度洗脱:0min,40%A,60%B;8min,40%A,60%B; 20min,20%A,80%B。
有益效果:与现有技术相比,本发明的特非那定有关物质的检验分离方法,特非那定与杂质A分离度大于5.0,各杂质间、其它已知杂质与特非那定间的分离度均大于1.5,符合要求,且主峰和主峰后面的未知杂质分离度可达3.5,确定本方法可作为检验方法使用,具有很好的实用性。
附图说明
图1是物质的紫外吸收扫描波长图;
图2是实施例1的混合溶液的色谱图;
图3是实施例2的混合溶液的色谱图;
图4是实施例3的混合溶液的色谱图;
图5是实施例4的混合溶液的色谱图。
具体实施方式
下面结合具体实施例,对本发明做进一步的说明。
实施例1
一种特非那定有关物质的检验分离方法,过程如下:
1)分别取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND适量,加70%乙腈制成10μg/mL的单一溶液,在 190nm~400nm波长进行全波长扫描,获得各物质的扫描波长,如表1和图1所示。
表1波长选择结果表
由图1看出,杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、特非那定紫外吸收相差较大,但在EP标准规定的检测波长(217nm)处均有较大吸收,结合欧洲药典质量标准及紫外扫描结果,将检测波长定为217nm。
2)有关物质色谱检验
混合溶液1:取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND各适量,加溶剂配制成每1mL约含杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J各 1.0μg(0.1%)、TFND 1.0mg的混合溶液。
色谱条件:色谱柱:Agilent 4.6mm*100mm*3.5μm。流动相A:乙腈-磷酸盐 (3.58g十二水合磷酸氢二钠溶于1000mL水中,磷酸调pH至6.3,再加入1.92g SDS溶解过滤)=20︰80;流动相B:乙腈。梯度洗脱:0min,60%A,40%B; 3min,55%A,45%B;30min,29%A,71%B。溶剂:45%乙腈。波长:217nm。流速:1.0mL/min。柱温:35℃。进样量:20μL。
取混合溶液进样,记录色谱图,结果如图2所示,显示各杂质能很好的分离,但是杂质F保留时间过长,且供试品中有未知杂质与已知杂质H分离不符合要求。
实施例2
特非那定有关物质的检验分离方法,同实施例1,其中,步骤2)中的色谱条件如下:
色谱柱:MZ-ANALYTICAL Column 250*4.6mm 100ODS-3 5μm。流动相A:乙腈-磷酸盐(3.58g十二水合磷酸氢二钠溶于1000mL水中,磷酸调pH至6.0,再加入1.92g SDS溶解过滤)=20︰80;流动相B:乙腈。梯度洗脱:0min,60%A,40%B;3min,55%A,45%B;20min,20%A,80%B。溶剂:乙腈-磷酸盐=45: 55。波长:217nm。流速:1.0mL/min。柱温:35℃。进样量:20μL。
取混合溶液进样,记录色谱图,如图3所示,结果表明,此条件下各杂质出峰时间较合理,但是未知杂质与杂质H不能很好的分离。
实施例3
特非那定有关物质的检验分离方法,同实施例2,其中,步骤2)中的色谱条件如下:
色谱柱:MZ-ANALYTICAL Column 250*4.6mm 100ODS-3 5μm。流动相A:乙腈-磷酸盐(3.58g十二水合磷酸氢二钠溶于1000mL水中,磷酸调pH至6.0,再加入1.92g SDS溶解过滤)=20︰80;流动相B:乙腈-甲醇=95︰5。梯度洗脱: 0min,40%A,60%B;10min,40%A,60%B;20min,20%A,80%B。溶剂:缓冲盐(pH6.0)-乙腈=40︰60。波长:217nm。流速:1.0mL/min。柱温:30℃。进样量:20μL。
取混合溶液2(同实施例1的混合溶液1配制,加溶剂(缓冲盐-乙腈=40︰ 60)配制成每1mL约含杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J各1.0μg(0.1%)、特非那定1.0mg的混合溶液) 进样,记录色谱图。
结果如图4所示,结果表明,调整后,未知杂质和杂质H分离度稍差。
实施例4
特非那定有关物质的检验分离方法,同实施例3,其中,步骤2)中的色谱条件如下:
色谱柱:MZ-ANALYTICAL Column 250*4.6mm 100ODS-3 5μm。流动相A:乙腈-磷酸盐(3.58g十二水合磷酸氢二钠溶于1000mL水中,磷酸调pH至6.0,再加入1.92g SDS溶解过滤)=20︰80;流动相B:乙腈-甲醇=95︰5。梯度洗脱: 0min,40%A,60%B;8min,40%A,60%B;20min,20%A,80%B。溶剂:缓冲盐(pH6.0)-乙腈=40︰60。波长:217nm。流速:1.0mL/min。柱温:30℃。进样量:20μL。
取混合溶液2依法进样,记录色谱图,结果如图5所示,表明,此色谱条件下特非那定与杂质A分离度大于5.0,各杂质间、其它已知杂质与特非那定间的分离度均大于1.5,符合要求。且主峰和主峰后面的未知杂质分离度可达3.5,确定本方法可作为检验方法使用。

Claims (8)

1.一种特非那定有关物质的检验分离方法,其特征在于,包括以下步骤:
1)分别取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND适量,加70%乙腈制成10µg/mL的单一溶液,在190nm~400nm波长进行全波长扫描,获得各物质的扫描波长,确定紫外扫描检测波长;
2)配制混合溶液:取杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J、TFND各适量,加溶剂配制成每1mL含杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G、杂质H、杂质I、杂质J各1.0μg、TFND 1.0mg的混合溶液;
3)色谱条件:色谱柱:MZ-ANALYTICAL Column 250*4.6mm 100ODS-3 5μm;流动相A:乙腈-磷酸盐=20︰80;流动相B:乙腈;梯度洗脱:0min,60%A,40%B;3min,55%A,45%B;20min,20%A,80%B;溶剂:乙腈-磷酸盐=45:55;波长:217nm;流速:1.0mL/min;柱温:30-35℃;进样量:20μL;
4)取混合溶液进样,记录色谱图,特非那定与各杂质均获得分离。
2.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤1)中,检测波长为217nm。
3.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,磷酸盐溶液配制方法为:3.58g十二水合磷酸氢二钠溶于1000mL水中,磷酸调pH至6.0-6.3,再加入1.92g SDS溶解过滤。
4.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,磷酸盐溶液的pH为6.0。
5.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,流动相B:乙腈-甲醇=95︰5。
6.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,梯度洗脱:0min,40%A,60%B;10min,40%A,60%B;20min,20%A,80%B。
7.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,柱温:30℃。
8.根据权利要求1所述的特非那定有关物质的检验分离方法,其特征在于,步骤3)中,梯度洗脱:0min,40%A,60%B;8min,40%A,60%B;20min,20%A,80%B。
CN201711450984.3A 2017-12-27 2017-12-27 一种特非那定有关物质的检验分离方法 Active CN108195962B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711450984.3A CN108195962B (zh) 2017-12-27 2017-12-27 一种特非那定有关物质的检验分离方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711450984.3A CN108195962B (zh) 2017-12-27 2017-12-27 一种特非那定有关物质的检验分离方法

Publications (2)

Publication Number Publication Date
CN108195962A true CN108195962A (zh) 2018-06-22
CN108195962B CN108195962B (zh) 2020-08-11

Family

ID=62584743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711450984.3A Active CN108195962B (zh) 2017-12-27 2017-12-27 一种特非那定有关物质的检验分离方法

Country Status (1)

Country Link
CN (1) CN108195962B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551079A (zh) * 2019-09-10 2019-12-10 株洲千金药业股份有限公司 一种高纯度盐酸地芬尼多的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007228824A (ja) * 2006-02-28 2007-09-13 Dai Ichi Seiyaku Co Ltd 薬物相互作用の検討方法
CN103969385A (zh) * 2014-05-08 2014-08-06 首都医科大学 荜茇及胡椒中的五种生物碱的鉴定及含量同步测定方法
CN106706789A (zh) * 2016-12-26 2017-05-24 江苏联环药业股份有限公司 用高效液相色谱法测定盐酸屈他维林注射液中有关物质的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007228824A (ja) * 2006-02-28 2007-09-13 Dai Ichi Seiyaku Co Ltd 薬物相互作用の検討方法
CN103969385A (zh) * 2014-05-08 2014-08-06 首都医科大学 荜茇及胡椒中的五种生物碱的鉴定及含量同步测定方法
CN106706789A (zh) * 2016-12-26 2017-05-24 江苏联环药业股份有限公司 用高效液相色谱法测定盐酸屈他维林注射液中有关物质的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BADWAN, AA 等: "TERFENADINE DETERMINATION USING DIFFERENT ANALYTICAL METHODS", 《ANALYTICAL LETTERS》 *
JAVID, FS 等: "APPLICATION OF SDS MICELLES AS CARRIERS FOR RELIABLE DETERMINATION OF FEXOFENADINE AND ITS IMPURITIES IN BULK AND PHARMACEUTICAL FORMULATIONS BY CAPILLARY MICELLAR ELCETROPHORESIS", 《JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES》 *
陈柳生 等: "特非那定片有关物质的检测方法研究", 《海峡药学》 *
龙娜 等: "HPLC法测定特非那定片中有关物质含量", 《中国药房》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551079A (zh) * 2019-09-10 2019-12-10 株洲千金药业股份有限公司 一种高纯度盐酸地芬尼多的制备方法

Also Published As

Publication number Publication date
CN108195962B (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
Kang et al. Comparison of ginsenoside contents in different parts of Korean ginseng (Panax ginseng CA Meyer)
Qian et al. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2
CN102579612B (zh) 一种准噶尔乌头总生物碱的提取方法
Li et al. A strategy to improve the oral availability of baicalein: The baicalein-theophylline cocrystal
Zhou et al. Simultaneous determination of caffeic acid derivatives by UPLC–MS/MS in rat plasma and its application in pharmacokinetic study after oral administration of Flos Lonicerae–Fructus Forsythiae herb combination
KR20140129306A (ko) 디안히드로갈락티톨 중의 불순물을 분석 및 결정하기 위한 개선된 분석 방법
Li et al. Chromatographic fingerprints analysis and determination of seven components in Danmu preparations by HPLC–DAD/QTOF-MS
Tsai et al. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection
Yi et al. HSCCC-based strategy for preparative separation of in vivo metabolites after administration of an herbal medicine: Saussurea laniceps, a case study
Zhu et al. Simultaneous determination of ferulic acid, paeoniflorin, and albiflorin in rat plasma by ultra‐high performance liquid chromatography with tandem mass spectrometry: application to a pharmacokinetic study of Danggui‐Shaoyao‐San
CN108195962A (zh) 一种特非那定有关物质的检验分离方法
Wang et al. Elution‐extrusion counter‐current chromatography separation of two new benzyl ester glucosides and three other high‐polarity compounds from the tubers of pleione bulbocodioides
WO2008131649A1 (en) Detection of blood plasma amygdalin of dissipating blood stasis botanical
Pandit et al. RP‐HPLC‐DAD for simultaneous estimation of mahanine and mahanimbine in Murraya koenigii
Hou et al. Characteristic chromatogram: a method of discriminate and quantitative analysis for quality evaluation of Uncaria stem with hooks
CN106442842B (zh) 一种西罗莫司的高效液相色谱检测方法
Gupta et al. Development of a validated UPLC–qTOF-MS/MS method for determination of bioactive constituent from Glycyrrhiza glabra
Zhao et al. pH‐Zone‐refining counter‐current chromatography for two new lipo‐alkaloids separated from refined alkaline extraction of Kusnezoff monkshood root
Yuan et al. Comparative studies on the multi-component pharmacokinetics of Aristolochiae Fructus and honey-fried Aristolochiae Fructus extracts after oral administration in rats
Yan et al. Preparative isolation and purification of capsaicin and dihydrocapsaicin from Capsici Fructus using supercritical fluid extraction combined with high speed countercurrent chromatography
Ji et al. A novel ultra high‐performance liquid chromatography‐tandem mass spectrometry method for the simultaneous determination of xanthones and steroidal saponins in crude and salt‐processed Anemarrhenae Rhizoma aqueous extracts
Tian et al. An improved highly sensitive method to determine low oxyresveratrol concentrations in rat plasma and its pharmacokinetic application
Zheng et al. Toxicokinetics of strychnine and brucine after the oral administration of Biqi capsule to rats by RRLC–MS/MS
Balaji et al. Validated chiral LC-ESI-MS/MS method for the simultaneous quantification of darolutamide diastereomers and its active metabolite in mice plasma: Application to a pharmacokinetic study
Liu et al. A rapid new approach for the quality evaluation of the folk medicine Dianbaizhu based on chemometrics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: 225000 No.9, Jiankang 1st Road, biological health industrial park, Hanjiang District, Yangzhou City, Jiangsu Province

Patentee after: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd.

Address before: 225006 No.21 Wenfeng Road, Guangling District, Yangzhou City, Jiangsu Province

Patentee before: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd.

CP02 Change in the address of a patent holder